FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely therapy and neurology, and concerns a melatonin agonist therapy. As the above melatonin agonist, (lR-Trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide is administered in effective doses that provides treating or preventing disruption of circadian rhythm or sleep disturbance.
EFFECT: invention provides treating or preventing disruption of circadian rhythm or sleep disturbance.
9 cl, 2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| WAY TO IMPROVE SLEEP | 2020 |
|
RU2804441C2 |
| COMPOSITIONS AND METHODS FOR TREATING INSOMNIA | 2015 |
|
RU2703297C2 |
| METHODS FOR TREATMENT OF DISORDERS OF CIRCADIAN SLEEP RHYTHM | 2017 |
|
RU2763493C2 |
| METHODS OF IMPROVING SLEEP AND PERFORMANCE AFTER SLEEP | 2019 |
|
RU2822076C2 |
| METHOD OF TREATING INSOMNIA | 2002 |
|
RU2560840C2 |
| METABOLITES (1R-TRANS)-N-[[2-(2,3-DIGIDRO-4-BENZOFURANYL)CYCLOPROPYL]-METHYL]PROPANAMIDE | 2013 |
|
RU2632889C2 |
| USE OF AN INVERSE AGONIST H3R FOR TREATING SLEEP DISORDER IN SHIFT WORK | 2018 |
|
RU2768894C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
| METHODS FOR USING CYCLIC AMIDE DERIVATIVES FOR TREATING SCHIZOPHRENIA | 2011 |
|
RU2576611C2 |
| AGENT FOR TREATMENT OF DESYNCHRONIZATION TROUBLES, AND PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2160101C2 |
